DHC
REGN icon

Drum Hill Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Drum Hill Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-300
Closed -$232K – 48
2026
Q1 		$232K Hold
300
– – 0.21% 43
2025
Q4 		$232K Buy
+300
New +$204K 0.24% 43
2025
Q1 		– Sell
-300
Closed -$214K – 47
2024
Q4 		$214K Buy
+300
New +$252K 0.27% 44

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Drum Hill Capital's REGN Position: Q2 2026 in Review

Drum Hill Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 300 shares — an estimated $232K sold.

Drum Hill Capital first reported a position in REGN in Q4 2024 and held it in 3 quarters. The position peaked at $232K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Drum Hill Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Drum Hill Capital sold 300 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $232K.
  • Drum Hill Capital first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Drum Hill Capital's Regeneron Pharmaceuticals position peaked at $232K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Drum Hill Capital's 13F filing for Q2 2026, filed 31 Jul 2026.